Rachel Klemovitch, Assistant Editor02.29.24
Argá Medtech announced the closure of a €54 million oversubscribed Series B funding. This will enable the company to further develop its CSE Pulsed Field Ablation (PFA) system designed to treat atrial fibrillation. The funding will also contribute towards an IDE study in the US and a CE Mark study in the EU.
Argá Medtech is a private company that has developed the Coherent Sine-Burst Electroporation (CSE) system. This is a next-generation cardiac ablation system that is designed to treat cardiac arrhythmias, including atrial fibrillation (AF).
This round of funding was led by existing investors, Avent Life Sciences in the UK, Earlybird Health in Germany, and Glide Healthcare, a new investor in the Netherlands.
With this finding, Argá also plans to expand its San Diego, CA offices in anticipation of its US clinical trials.
“We are pleased to secure the support of such marquee investors who believe that Argá Medtech will revolutionize the atrial fibrillation ablation field,” Argá Medtech CEO, David Neale told the press. “This financing enables us to advance toward our goal of validating the CSE™ PFA system in Europe and the US as we work to deliver a safe, fast, and effective treatment to millions of people affected by cardiac rhythm disorders and atrial fibrillation. We are proud of our accomplishments to date, including conducting a 48-patient first-in-human study in Europe, which demonstrated the high performance of our platform in treating atrial fibrillation.”
The CSE ablation system uses electrophysiologists to safely and efficiently treat any region of the heart. The system uses a single, multi-configurable catheter while titrating lesion depths according to the location in the heart. A PFA generation and a multi-configurable catheter is combined to provide a flexible AF treatment.
Rather than using square wave energy sources, Argá uses a sinusoidal/sine wave powering system. This allows physicians to configure energy delivery and titrate the depth location in the heart. This waveform is delivered through a catheter that can be shaped to create linear, circular, or focal ablation lesions. The overall procedure is simplified to reduce cost and reduce the risk of air bubbles as one catheter is removed and another is inserted.
Argá Medtech is a private company that has developed the Coherent Sine-Burst Electroporation (CSE) system. This is a next-generation cardiac ablation system that is designed to treat cardiac arrhythmias, including atrial fibrillation (AF).
This round of funding was led by existing investors, Avent Life Sciences in the UK, Earlybird Health in Germany, and Glide Healthcare, a new investor in the Netherlands.
With this finding, Argá also plans to expand its San Diego, CA offices in anticipation of its US clinical trials.
“We are pleased to secure the support of such marquee investors who believe that Argá Medtech will revolutionize the atrial fibrillation ablation field,” Argá Medtech CEO, David Neale told the press. “This financing enables us to advance toward our goal of validating the CSE™ PFA system in Europe and the US as we work to deliver a safe, fast, and effective treatment to millions of people affected by cardiac rhythm disorders and atrial fibrillation. We are proud of our accomplishments to date, including conducting a 48-patient first-in-human study in Europe, which demonstrated the high performance of our platform in treating atrial fibrillation.”
The CSE ablation system uses electrophysiologists to safely and efficiently treat any region of the heart. The system uses a single, multi-configurable catheter while titrating lesion depths according to the location in the heart. A PFA generation and a multi-configurable catheter is combined to provide a flexible AF treatment.
Rather than using square wave energy sources, Argá uses a sinusoidal/sine wave powering system. This allows physicians to configure energy delivery and titrate the depth location in the heart. This waveform is delivered through a catheter that can be shaped to create linear, circular, or focal ablation lesions. The overall procedure is simplified to reduce cost and reduce the risk of air bubbles as one catheter is removed and another is inserted.